INTRODUCTION
Cerebral infarction (CI), also known as ischemic stroke, refers to the local brain blood circulation disorders, ischemia, and hypoxia due to softening of necrosis. The clinical symptoms of cerebral infarction are complex. The occurrence of cerebral infarction is associated with parts of the damage, the severity of cerebral ischemia, and prior to the onset of other diseases, etc. 1 People usually suffer CI at the age of 50-60, but now this situation is becoming younger, so the incidence of cerebral infarction has severely influenced human health. 2 At present, the main way to treat cerebral infarction include: thrombolytic therapy, platelet aggregation therapy, anticoagulant therapy, reduced fiber treatment and Traditional Chinese Medicine therapy. 3 At now, a large number of clinical trials show that injections of ginkgo (GI) has a significant effect in treating cerebral infarction, including ginkgo-dipyidamolum injections (GD), shuxuening injections (SXN), ginaton injections (GbE), ginkgolides injections (GK) and floium ginkgo extract and tertram ethypyrazine sodium chloride injections (FT). Total flavones of ginkgo biloba have the function of dilated coronary arteries and cerebrovascular, improvement in the symptoms of cerebral ischemia. Some researchers performed systematic reviews and standard Meta-analyses on clinical effectiveness and safety of GI combined with Western Medicine (WM) in treatment of CI. However, standard Meta-analysis is unable to include all direct and indirect comparisons among five types of GI in one analysis, while network Meta-analysis (NMA) can conduct a more accurate ranking and precision for the current therapeutic strategies. We aimed to provide a clinically useful summary of the results of the multiple-treatments Meta-analysis that can be used to guide treatment decisions.
MATERIALS AND METHODS

Searching strategy
Literature search was conducted in several databases including the China National Knowledge Infrastructure Database (CNKI), the Chinese Scientific Journals Database (VIP), Wanfang Database, Web of Science, the Chinese Biomedical Literature Database (CBM), PubMed, Embase, and the Cochrane Library, with the publication data no later than April, 2016. Chinese search terms include: English search terms include: shuxuening injections, brain infarction, ischemic stroke, cerebral infarction, ginaton injections, ginkgo leaf extract and dipyridamole injections, ginkgolide injections, floium ginkgo extract and tertram ethypyrazine sodium chloride injections. In PubMed, for example, the specific search strategies of PubMed as following: #1 "brain infarction" [ 
Inclusion criteria
Studies meeting the following criteria were included: (a) Randomized controlled trials (RCTs) used GI as an adjuvant treatment of CI, regardless of blinding. (b) The diagnosis of CI was according to the fourth national cerebrovascular diseases conferences in 1995. 4 No limitation was placed on age, gender, race or severity of disease. (c) The control group and experimental group were both given WM therapy, including neuroprotective agents, anticoagulants, dehydration, thrombolysis, energy mixture, and calcium antagonists. On the basis of that, experimental group was added one type of CI. (d) The primary outcomes were the total effectiveness of CI. Basic heal was determined when the neurological deficit score decreased by between 90% and 100%, and the level of Sick is "0". Significant progress was determined when the neurological deficit score decreased by between 46% and 90%, and the level of Sick is between "1" and "3". Progress was determined when the neurological deficit score decreased by between 18% and 45% . No change was determined when the functional deficit score decreased by < 17%. Worsen was determined when the functional deficit score increase. The secondary outcomes were the changes of neural function defect score (NFDS) and adverse drug reactions /adverse drug events (ADRs/ADEs).
Exclusion criteria
Data was incorrect, incomplete or not available and without separate evaluation of the individual drug were excluded. Besides, reviews, conference abstracts, comments, and research proposal were excluded.
Data extraction and quality assessment
Two investigators (Tan Di, Liu Shi) independently conducted the literature searching, study selection, data extraction, and assessment of risk of bias. Information extraction included authors, year of publication, study size, participants' age and gender, intervention measurements, outcomes and ADRs by the use of pre-designed forms. The quality assessment was conducted by The Cochrane Risk Assessment Tool, which included random sequence generation, blinding of outcome assessment, blinding of participants and personnel, allocation concealment, selective reporting, incomplete outcome data, and other biases. Each study was rated "high", "unclear", or "low". "High" refers to the random method is not correct, or no allocation concealment or no blinding. "Unclear" means the results are not described in this paper. "Low" means correct random methods, appropriate blinding without being violated through implementation, and a detailed description in the article. Any disagreements were resolved by a third researcher (Wu Jiarui).
Statistical analysis (a) Systematic review methods: Review Manager Software (version 5.3), provided by the Cochrane Collaboration was, used for the data analysis. Data was summarized by using relative risk (RR) or mean difference (MD) with 95% confidence interval (CI). The heterogeneity of original studies was evaluated with χ 2 test and Ⅰ-squared statistic. When P > 0.1 and I ² < 50%, a fixed-effect model was used to pool the results; otherwise, a random-effect model was used. (b) NMA methods: Results are reported as odds ratios (OR) or standard mean difference (SMD) with 95% CI for all comparisons of interventions. Initially, the data were analyzed by Stata13.0 software which to draw network diagram. Then, we used the WinBUGS14 software (MRC Biostatistics Unit, Cambridge, UK) to conduct Bayesian network Meta-analyses. 5, 6 We calculated 95%CI for OR using the Markov Chain Monte Carlo methods. Besides, in order to check the consistency of the NMA results, we conducted the inconsistency analysis by using the Stata software. These ranking probabilities were used to calculate the Surface under the Cumulative Ranking curve (SUCRA), which is expressed as percentage (100% for the best intervention and 0% for the worst intervention and approximately 50% for equivalent interventions).
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RESULTS
Searching and filtering results
The initial search yielded 1740 studies, and then 321 studies were excluded. With further text reading, 37 studies were selected after removing case studies and literatures that did not meet the inclusion criteria. All 37 papers were in Chinese and published no later than April, 2016. (Figure 1 )
Characteristics of included studies
In total 4330 patients were involved in the Meta-analysis. The average age of the patients was approximately between 50 and 70 years. About two-thirds of participants (64% ) were men. Only 11 studies had a course of treatment longer than 2 weeks. Experimental group vs control group: GbE + WM vs WM, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] GD + WM vs WM, [20] [21] [22] [23] SXN + WM vs WM, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] GK + WM vs GD + WM, 42 GK + WM vs SXN + WM, 43 FT + WM vs WM. 44 More details are shown in Table 1 , the star structure network diagram of 5 kinds of GI and WM as shown in Figure 2 .
Quality evaluation on included studies
To evaluate the quality of research by the use of the Cochrane Risk of Bias Tool, randomized of participants was mentioned in all trials; however, only 4 
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Meta-analysis results
Seventeen RCTs reported the total effectiveness of SXN in treatment of CI, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] following the test of heterogeneity (P = 0.44, I 2 = 1%), a fixed effects model was adopted for merging data. The results showed that compared to the control group, combined SXN and WM was better than WM alone in improving the total effectiveness of CI [OR = 3.57, 95% CI (2.75, 4.64), P < 0.0001]. Three RCTs reported the total effectiveness of GD in treatment of CI, 20, 21, 23 following the test of heterogeneity (P = 0.71, I 2 = 0%), a fixed effects model was adopted for merging data. The results showed that compared to the control group, combined GD and WM was better than WM alone in improving the total effectiveness of CI [OR = 5.38, 95% CI (2.73, 10.60), P < 0.0001]. Nine RCTs reported the total effectiveness of GbE in treatment of CI, [9] [10] [11] [12] [13] [14] [15] [16] [17] following the test of heterogeneity (P = 0.99, I 2 = 0%), a fixed effects model was adopted for merging data. The results showed that compared to the control group, combined GbE and WM was better than WM alone in improving the total effectiveness of CI [OR = 3.19, 95% CI (2.13, 4.77), P < 0.0001] (Figure 4 ).
Neural function defect score
Nine RCTs reported NFDS of SXN in treatment of CI, 25, 26, [29] [30] [31] [32] 34, 36 following the test of heterogeneity (P < 0.000 01, I 2 = 97%), a random effects model was adopted for merging data. The result showed that the experimental group was more effective in reducing NFDS (MD = -4.93, 95% CI (-6.92, 2.94), P < 0.0001). Two RCTs reported NFDS of GD in treatment of CI, 20, 22 following the test of heterogeneity (P = 0.07, I 2 = 70% ), a random effects model was adopted for merging data. The result showed that the experimental group was more effective in reducing NFDS [MD = -4.25, 95% CI (-7.33, 1.18), P < 0.0001].
Five RCTs reported NFDS of GbE in treatment of CI, 8, 14, 15, 18, 19 following the test of heterogeneity (P < 0.000 01, I 2 = 87%), a random effects model was adopted for merging data. The result showed that the experimental group was more effective in reducing NFDS [MD = -3.74, 95% CI (-4.94, -2.55), P < 0.000 01, Figure 5 ]. (Table 3) . The result of probability sort displayed that GK + WM (SUCRA = 98.03%) is the best treatment measures to improve the efficiency in cerebral infarction. In turn provide GD + WM (SUCRA = 73.34% ), SXN + WM (SUCRA = 46.59% ), GbE + WM (SU-CRA = 45.46% ), FT + WM (SUCRA = 35.64% ) ( Figure 6 ).
Network meta-analysis results
Inconsistency test
One square loop was present in the network Meta-analysis, including WM, GD + WM, GK + WM, SXN + WM. So the result of inconsistency test displayed that there was no inconsistency between direct comparison and indirect comparison (ROR = 1.046) (Figure 7 ).
Neural function defect score
There are 17 8,14,15,18-20,22,25,26.29-32,34,36,41,43 research reported on the NFDS of injections of ginkgo combined with Western Medicine in treating cerebral infarction. Injections of ginkgo include GbE, GD, SXN and GK. The following treatment comparisons were statistically significant: GbE plus WM versus WM (OR = -0.49, 95% CI (-0.63, -0.31)); GD plus WM versus WM (OR = -0.39, 95%CI (-0.64, -0.15)); SXN plus WM versus WM (OR = -0.42, 95% CI ( -0.57, -0.29); GK plus WM versus WM (OR = -0.61, 95%CI ( -1.12, -0.03)). Other treatment comparisons failed to reach statistical significance (Table 3) . The results of probability sort displayed that GK + BO 2014 16 Chen 2015 22 Gao 2011 31 Gu 2014 38 Gu 2015 19 Guo 2013 
Safety
Among the 37 included studies, there were 9 studies 11, 17, 20, 28, 30, 37, 38, 40, 42 mentioned no ADRs/ADEs. Twenty-one of them that did not produce any ADRs/ADEs and other 7 papers 8, 9, 26, 31, 35, 43, 44 produced ADRs/ADEs. The ADRs/ ADEs of injections of ginkgo reported in 24 cases which included headache, facial flushing, chest tightness, dizziness, gastrointestinal discomfort, etc. The ADRs/ADEs of WM reported in 5 cases which included headache, gastrointestinal discomfort, low blood pressure, etc.
DISCUSSION
In this study the data used for network Meta-analysis in this research includes regular Cerebral Infarction (CI) treatment of 5 kinds of injections of ginkgo with WM. The results show that the efficacy of GbE, GD, SXN, GK and FT with WM is better than only WM. And GK, GD, GbE with WM may be the most efficient treatment measures in clinical efficiency sorting results. Using GbE, GD, SXN and GK has more incidence than using only WM in NFDS aspects. In ADR/ ADEs aspect,the incidence of ADR/ADE rates are significantly higher in injections of ginkgo group than in using WM only group. But there are still 21 studies do not describe ADR/ADE, the safety of injections of ginkgo is still waiting for being tested with high quality clinical experiment. Some limitations exist in our study. In all 37 studies, all experiments did not report whether they used blind method or allocation concealment so that it was likely to have selection bias, performance bias or detection bias, which may lead to exaggerated results. Only 4 articles 8, 18, 19, 37 were referred using the random number table method, the rest of articles didn't describe the definite method of randomized. All the research had full sample size. Besides, there is only one article for GK, which the statistical efficiency might be not good enough. In summary, the quality of injections of ginkgo clinical experiment still needed to be further promoted in order to ensure the reliability of the results of network Meta-analysis. Through the network Meta-analysis of RCTs regarding injections of ginkgo in the treatment of CI, the combined use of GK and WM may be the best treatment measures. However, due to the limitations of the study, more qualified studies should be conducted for the assessment of efficacy and safety of STS for UAP. Figure 6 Ranking for the total effective rate of cerebral infarction Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among the 5 GI. 1: WM; 2: GbE + WM; 3: GD + WM; 4: SXN + WM; 5: GK + WM; 6: FT + WM. GD: ginkgo-dipyidamolum injections; SXN: shuxuening injections; GbE: ginaton injections; GK: ginkgolides injections; FT: floium ginkgo extract and tertram ethypyrazine sodium chloride injections; WM: Western Medicine. Rank Figure 8 Ranking for neural function defect score of cerebral infarction Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among the 4 GI. 1: WM; 2: GbE + WM; 3: GD + WM; 4: SXN + WM; 5: GK + WM. GD: ginkgo-dipyidamolum injections; SXN: Shuxuening injections; GbE: ginaton injections; GK: ginkgolides injections; WM: Western Medicine. 
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